---
title: "Spondyloarthropathies"
order: 3
category: "Rheumatology"
---

# Spondyloarthropathies

## Overview

Spondyloarthropathies (SpA) are a group of inflammatory rheumatic diseases that share common clinical, genetic, and pathophysiologic features. They primarily affect the axial skeleton (spine and sacroiliac joints) but also involve peripheral joints, entheses (insertion sites of tendons and ligaments), and extra-articular structures. Unlike rheumatoid arthritis, spondyloarthropathies are typically seronegative (RF and anti-CCP negative) and strongly associated with HLA-B27.

### Classification

**Axial spondyloarthritis (axSpA)**:
- **Ankylosing spondylitis (AS)**: Radiographic sacroiliitis present
- **Non-radiographic axial SpA (nr-axSpA)**: No radiographic sacroiliitis but MRI evidence or clinical/laboratory findings

**Peripheral spondyloarthritis**:
- **Psoriatic arthritis (PsA)**
- **Reactive arthritis (ReA)**
- **Inflammatory bowel disease-associated arthritis** (IBD-SpA)
- **Undifferentiated spondyloarthritis**

### Epidemiology

- Prevalence: 0.5-1.5% of general population
- Age of onset: Typically 15-45 years (peak 20s-30s)
- Male predominance in axial SpA (AS 3:1), equal in peripheral SpA
- HLA-B27 prevalence:
  - General population: 6-8% (Caucasians), <1% (African Americans), 15-50% (certain Native American tribes)
  - AS patients: 85-95%
  - Risk of AS if HLA-B27 positive: 5% overall, 20% if first-degree relative has AS

### Common Features

**Clinical**:
- Inflammatory back pain (versus mechanical back pain)
- Asymmetric peripheral arthritis (lower extremity predominance)
- Enthesitis (Achilles, plantar fascia, patellar tendon, costochondral junctions)
- Dactylitis ("sausage digit")
- Extra-articular manifestations: Uveitis, psoriasis, inflammatory bowel disease

**Laboratory**:
- HLA-B27 positive (not diagnostic, only risk factor)
- Elevated inflammatory markers (ESR, CRP)
- Seronegative (RF and anti-CCP negative)

**Imaging**:
- Sacroiliitis (hallmark)
- Syndesmophytes (vertical bony bridging in spine)
- Bamboo spine (advanced AS)
- Enthesophytes

## Pathophysiology

### Genetic Factors

**HLA-B27**:
- Strongest genetic association
- Relative risk 50-100 fold for AS
- Mechanisms proposed:
  - Misfolding hypothesis: HLA-B27 heavy chains misfold → ER stress → IL-23 production
  - Arthritogenic peptide presentation
  - Homodimerization on cell surface

**Non-HLA genes**:
- IL-23 receptor (IL23R)
- ERAP1 (endoplasmic reticulum aminopeptidase 1)
- IL-12B, STAT3, TYK2

### Immunopathogenesis

**IL-23/IL-17 axis**:
- Central pathway in SpA pathogenesis
- IL-23 stimulates Th17 cells
- IL-17 promotes inflammation at entheses and synovium
- TNF-α amplifies inflammation
- Therapeutic targets: TNF, IL-17, IL-12/23

**Enthesitis**:
- Primary site of inflammation
- Mechanical stress + genetic susceptibility
- Entheseal inflammation → new bone formation
- Can lead to syndesmophyte formation and ankylosis

**Gut-joint axis**:
- Subclinical gut inflammation in 40-60% of AS patients
- Gut dysbiosis may trigger disease
- HLA-B27 interacts with gut microbiome

## Ankylosing Spondylitis

### Clinical Presentation

**Inflammatory back pain** (hallmark):
- Age of onset <45 years
- Insidious onset
- Duration >3 months
- Morning stiffness >30 minutes
- Improves with exercise, not with rest
- Nocturnal pain (second half of night)
- Alternating buttock pain (sacroiliitis)

**Physical examination**:
- Reduced spinal mobility:
  - **Schober test**: <5 cm expansion (mark 10 cm above L5, measure after full forward flexion)
  - **Chest expansion**: <5 cm (at 4th intercostal space)
  - **Occiput-to-wall distance**: Should be 0 cm
  - **Lateral spinal flexion**: Reduced
- Loss of lumbar lordosis
- Increased thoracic kyphosis
- Cervical spine involvement (late): Forward neck posture
- Sacroiliac joint tenderness

**Peripheral arthritis** (30-40%):
- Asymmetric oligoarthritis
- Lower extremity predominance (hips, knees, ankles)
- Hip involvement (25-35%): Poor prognostic factor

**Enthesitis** (50%):
- Achilles tendinitis
- Plantar fasciitis
- Costochondral junctions
- Greater trochanter, iliac crest, ischial tuberosity

### Extra-Articular Manifestations

**Acute anterior uveitis** (25-40%):
- Most common extra-articular manifestation
- Painful red eye, photophobia, blurred vision
- Usually unilateral and recurrent
- Requires urgent ophthalmology evaluation
- Treatment: Topical corticosteroids, mydriatics

**Cardiovascular** (2-10%):
- Aortitis and aortic regurgitation
- Conduction abnormalities (heart block)
- Increased CV risk (chronic inflammation)

**Pulmonary** (1-2%):
- Apical pulmonary fibrosis
- Restrictive lung disease (chest wall rigidity)

**Renal**:
- IgA nephropathy (rare)
- AA amyloidosis (rare with modern therapy)

**Neurologic**:
- Cauda equina syndrome (rare, late complication)
- Atlantoaxial subluxation (rare)
- Spinal fractures (ankylosed spine is brittle)

### Diagnosis

**Classification criteria** (ASAS 2009 for axial SpA):

**Imaging arm**:
- Sacroiliitis on imaging (X-ray or MRI) PLUS ≥1 SpA feature

**Clinical arm**:
- HLA-B27 positive PLUS ≥2 SpA features

**SpA features**:
- Inflammatory back pain
- Arthritis
- Enthesitis
- Uveitis
- Dactylitis
- Psoriasis
- Inflammatory bowel disease
- Good response to NSAIDs
- Family history of SpA
- HLA-B27 positive
- Elevated CRP

**Laboratory**:
- HLA-B27: 85-95% positive in AS
- ESR, CRP: Elevated in 50-70% (correlates with disease activity)
- RF, anti-CCP: Negative (helps exclude RA)
- CBC, CMP: Baseline

**Imaging**:
- **Radiography**:
  - **Sacroiliac joints** (AP pelvis or Ferguson view):
    - Grade 0: Normal
    - Grade 1: Suspicious
    - Grade 2: Minimal (erosions or sclerosis)
    - Grade 3: Moderate (erosions, sclerosis, widening/narrowing)
    - Grade 4: Ankylosis (fusion)
  - **AS diagnosis**: Bilateral grade ≥2 or unilateral grade 3-4
  - **Spine**: Squaring of vertebrae, syndesmophytes, bamboo spine (late)

- **MRI**:
  - More sensitive than X-ray for early disease
  - **STIR sequence**: Bone marrow edema (active inflammation)
  - **T1 post-gadolinium**: Enthesitis, synovitis
  - Can detect sacroiliitis years before X-ray changes

- **Ultrasound or MRI**: Enthesitis evaluation

**Differential diagnosis**:
- Mechanical back pain (>90% of low back pain)
- Diffuse idiopathic skeletal hyperostosis (DISH): Flowing ossification, older age, no sacroiliitis
- Degenerative disc disease
- Osteitis condensans ilii: Benign sclerosis of iliac side of SI joints (young women)

### Treatment

**Goals**:
- Reduce pain and stiffness
- Maintain spinal mobility and function
- Prevent structural damage
- Improve quality of life

**Physical therapy** (all patients):
- Spinal mobility exercises
- Posture training
- Swimming and stretching
- Most important non-pharmacologic intervention

**NSAIDs** (first-line pharmacotherapy):
- Continuous use preferred over on-demand
- Can slow radiographic progression (controversial)
- Examples: Naproxen 500 mg BID, indomethacin 75 mg BID, celecoxib 200 mg BID
- Trial 2-4 weeks at full dose before switching
- GI and CV risk assessment

**Biologic DMARDs**:

**Indications**:
- Persistently high disease activity despite NSAIDs
- BASDAI ≥4 (0-10 scale) or ASDAS ≥2.1

**TNF inhibitors** (first-line biologics):
- **Adalimumab**: 40 mg SC every 2 weeks
- **Etanercept**: 50 mg SC weekly
- **Infliximab**: 5 mg/kg IV at 0, 2, 6 weeks, then every 6-8 weeks
- **Golimumab**: 50 mg SC monthly or 2 mg/kg IV every 8 weeks
- **Certolizumab**: 200 mg SC every 2 weeks or 400 mg every 4 weeks

- Efficacy: 50-60% achieve ASAS40 response
- Work for axial and peripheral disease
- Do not slow radiographic progression of spine (syndesmophytes still form)
- Screening: TB, hepatitis B and C (as in RA)

**IL-17 inhibitors** (if TNF inadequate or contraindicated):
- **Secukinumab**: 150 mg SC weekly x5, then monthly (300 mg if needed)
- **Ixekizumab**: 160 mg SC x1, then 80 mg every 2-4 weeks

- Efficacy: Similar to TNF inhibitors
- May be more effective for peripheral arthritis and enthesitis
- Lower infection risk than TNF inhibitors
- More frequent Candida infections, IBD flares possible

**JAK inhibitors**:
- **Tofacitinib**: 5 mg PO BID (off-label for AS, approved for PsA)
- **Upadacitinib**: 15 mg PO daily (approved for AS)

- Efficacy: Similar to TNF inhibitors
- Oral administration
- Risks: Infections, VTE, malignancy

**NOT effective** in axial SpA:
- Conventional DMARDs (methotrexate, sulfasalazine, leflunomide)
- Exception: Sulfasalazine may help peripheral arthritis

**Glucocorticoids**:
- Limited role in axial SpA (unlike RA)
- Intra-articular or peritendinous injections for peripheral arthritis or enthesitis
- Avoid chronic systemic use

**Surgery**:
- Total hip replacement: End-stage hip arthritis
- Spinal osteotomy: Severe kyphotic deformity
- Vertebral fracture fixation

**Monitoring**:
- BASDAI (Bath AS Disease Activity Index): Patient-reported (0-10 scale)
- ASDAS (AS Disease Activity Score): Includes CRP or ESR
- BASFI (Bath AS Functional Index): Function assessment
- CRP/ESR every 3-6 months
- Radiographs every 2-3 years (assess progression)
- TB screening before biologics

## Psoriatic Arthritis

### Clinical Presentation

**Arthritis patterns**:
- **Asymmetric oligoarthritis** (most common, 40%): <5 joints, asymmetric
- **Symmetric polyarthritis** (30-40%): Resembles RA but DIP involvement
- **Distal interphalangeal (DIP) predominant** (10%): Classic pattern
- **Arthritis mutilans** (<5%): Severe destructive arthritis, "pencil-in-cup" deformity
- **Spondylitis** (40%): Axial involvement, often with peripheral arthritis

**Psoriasis**:
- Precedes arthritis in 70-80% (average 10 years before)
- Concurrent in 10-15%
- Arthritis before psoriasis in 10-15%
- Severity of skin disease does not correlate with arthritis severity
- Nail involvement: Pitting, onycholysis, oil spots (80% with arthritis)

**Enthesitis** (30-50%):
- Achilles, plantar fascia, extensor tendon insertions

**Dactylitis** (40-50%):
- "Sausage digit": Diffuse swelling of entire finger or toe
- Combination of synovitis, tenosynovitis, and soft tissue edema

**Axial involvement** (40%):
- Spondylitis and sacroiliitis
- Unilateral sacroiliitis more common than AS
- Asymmetric, bulky syndesmophytes

### Diagnosis

**CASPAR criteria** (sensitivity 91%, specificity 99%):
- Established inflammatory arthritis PLUS ≥3 points:
  - Current psoriasis (2 points)
  - History of psoriasis (1 point)
  - Family history of psoriasis (1 point)
  - Dactylitis (1 point)
  - Nail dystrophy (1 point)
  - RF negative (1 point)
  - Juxta-articular new bone formation on X-ray (1 point)

**Laboratory**:
- No specific test for PsA
- RF and anti-CCP: Negative (5-10% may be positive)
- HLA-B27: Positive in 20% (higher if axial involvement)
- Elevated ESR, CRP in active disease
- Hyperuricemia common (can coexist with gout)

**Imaging**:
- **X-ray**: Erosions, joint space narrowing, periostitis, pencil-in-cup deformity, ankylosis
- **MRI**: Synovitis, enthesitis, dactylitis, bone marrow edema
- **Ultrasound**: Enthesitis, tenosynovitis, synovitis

### Treatment

**NSAIDs**: First-line for mild disease

**Conventional DMARDs**:
- **Methotrexate**: 15-25 mg weekly (also treats psoriasis)
  - First-line DMARD for PsA
  - Efficacy: Modest for arthritis, good for skin
- **Sulfasalazine**: Peripheral arthritis (not skin or axial)
- **Leflunomide**: Alternative to methotrexate
- **Apremilast** (PDE4 inhibitor): Oral, for mild disease (arthritis and skin)

**Biologic DMARDs**:

**TNF inhibitors** (first-line biologics):
- Treat arthritis, enthesitis, dactylitis, axial disease, and skin
- Adalimumab, etanercept, infliximab, golimumab, certolizumab

**IL-17 inhibitors**:
- Secukinumab, ixekizumab
- Superior skin efficacy compared to TNF inhibitors
- Effective for arthritis, enthesitis, dactylitis, axial disease

**IL-12/23 inhibitors**:
- **Ustekinumab**: 45 mg or 90 mg SC at 0, 4 weeks, then every 12 weeks
- **Guselkumab**: 100 mg SC at 0, 4 weeks, then every 8 weeks
- Effective for skin and arthritis
- Less effective for axial disease

**JAK inhibitors**:
- Tofacitinib: 5 mg BID
- Upadacitinib: 15 mg daily
- Effective for arthritis, less studied for skin

**Treatment approach**:
1. NSAIDs ± intra-articular steroids (mild disease)
2. Add methotrexate (moderate disease)
3. Switch to biologic if inadequate response (TNF inhibitor, IL-17, or IL-12/23)
4. Assess skin and joint disease separately (may need combination therapy)

## Reactive Arthritis

### Definition and Etiology

**Reactive arthritis (ReA)**: Sterile arthritis following infection at distant site (usually GI or GU)

**Triggering infections**:
- **Gastrointestinal**:
  - *Salmonella*, *Shigella*, *Yersinia*, *Campylobacter*
- **Genitourinary**:
  - *Chlamydia trachomatis* (most common in developed countries)
  - *Ureaplasma urealyticum*
- **Respiratory** (rare):
  - *Chlamydia pneumoniae*, *Mycoplasma*

**Epidemiology**:
- Incidence: 30-40 per 100,000
- Age: Young adults (20-40 years)
- Male predominance (especially post-GU infection)
- HLA-B27 positive: 60-80% (predicts more severe, chronic disease)

### Clinical Presentation

**Classic triad** (30-50%):
- Arthritis
- Urethritis
- Conjunctivitis

**Arthritis**:
- Onset 1-4 weeks after infection
- Asymmetric oligoarthritis
- Lower extremity predominance (knees, ankles, feet)
- Enthesitis and dactylitis common

**Urethritis/cervicitis**:
- Dysuria, urethral discharge
- May be asymptomatic in women

**Ocular**:
- Conjunctivitis (30-60%): Mild, bilateral, self-limited
- Uveitis (12%): Anterior uveitis, more severe

**Mucocutaneous**:
- **Keratoderma blennorrhagicum**: Hyperkeratotic lesions on soles/palms (like pustular psoriasis)
- **Circinate balanitis**: Painless lesions on glans penis
- **Oral ulcers**: Usually painless

**Axial involvement** (rare in early disease)

### Diagnosis

**Clinical diagnosis** (no specific test):
- Arthritis + recent infection + negative cultures from joint

**Laboratory**:
- Synovial fluid: Inflammatory (WBC 2,000-50,000), sterile
- HLA-B27: Positive in 60-80%
- ESR, CRP: Elevated
- Stool culture or PCR: Identify GI pathogen
- GU testing: Chlamydia PCR (urine or swab)

**Imaging**: Similar to other SpA (enthesitis, periostitis)

### Treatment

**Antibiotics**:
- Treat acute Chlamydia infection (doxycycline 100 mg BID x7 days or azithromycin 1g x1)
- No benefit for prolonged antibiotics in established arthritis
- Treat GI infection if ongoing symptoms

**NSAIDs**: First-line for arthritis (2-4 weeks)

**Intra-articular corticosteroids**: Persistent monoarthritis

**DMARDs** (if chronic, >6 months):
- Sulfasalazine 2-3 g daily (first-line)
- Methotrexate (alternative)

**Biologics** (refractory chronic disease):
- TNF inhibitors

**Prognosis**:
- Self-limited in 50% (resolves in 3-6 months)
- Chronic or recurrent in 30-50%
- HLA-B27 positive, initial severity, axial involvement predict chronicity

## Inflammatory Bowel Disease-Associated Arthritis

### Types

**Axial arthritis** (10-25% of IBD patients):
- Spondylitis and sacroiliitis
- Independent of IBD activity
- HLA-B27 association
- Treatment: NSAIDs (with caution in IBD), TNF inhibitors, IL-12/23 inhibitors

**Peripheral arthritis** (10-20% of IBD patients):

**Type 1** (pauciarticular):
- <5 large joints (knees, ankles, hips, wrists, elbows)
- Acute, self-limited episodes
- Parallels IBD activity
- Treatment: Treat underlying IBD, intra-articular steroids, avoid NSAIDs

**Type 2** (polyarticular):
- ≥5 small joints (MCPs, PIPs, MTPs)
- Chronic, symmetric
- Independent of IBD activity
- Treatment: DMARDs, biologics

**Enthesitis** (1-10%)

### Extra-Intestinal Manifestations

- Arthritis
- Erythema nodosum (IBD flare-related)
- Pyoderma gangrenosum
- Uveitis
- Primary sclerosing cholangitis (associated with UC)

### Treatment

**TNF inhibitors**:
- Treat both IBD and arthritis
- Infliximab, adalimumab, golimumab, certolizumab

**IL-12/23 inhibitors**:
- Ustekinumab: Crohn's disease and arthritis

**JAK inhibitors**:
- Tofacitinib: UC and arthritis

**Avoid**:
- NSAIDs (may exacerbate IBD)
- Methotrexate monotherapy (less effective for IBD)

## Prognosis

### Ankylosing Spondylitis
- Progressive spinal fusion over years (variable rate)
- Functional decline if untreated
- Biologics reduce disease activity but don't prevent syndesmophytes
- Normal life span with modern treatment
- Increased CV mortality

### Psoriatic Arthritis
- 40-50% develop erosive disease if untreated
- Early treatment with DMARDs/biologics prevents progression
- Arthritis mutilans in <5% (severe, destructive)

### Reactive Arthritis
- 50% self-limited (resolves in months)
- 30-50% chronic or recurrent
- HLA-B27 positive worse prognosis

### IBD-Associated Arthritis
- Type 1: Self-limited with IBD treatment
- Type 2 and axial: Chronic, requires ongoing therapy

## Key Points

- Spondyloarthropathies are seronegative inflammatory arthritides characterized by axial involvement, asymmetric oligoarthritis, enthesitis, and HLA-B27 association
- Inflammatory back pain criteria: Age <45, insidious onset, >3 months duration, morning stiffness >30 min, improves with exercise
- Ankylosing spondylitis requires sacroiliitis on imaging (X-ray or MRI); NSAIDs first-line, TNF/IL-17 inhibitors for inadequate response
- Psoriatic arthritis has diverse presentations; treat with methotrexate first-line, biologics (TNF, IL-17, IL-12/23 inhibitors) for moderate-severe disease
- Reactive arthritis is sterile arthritis following GI or GU infection; treat acute Chlamydia, use NSAIDs/DMARDs for chronic arthritis
- Extra-articular manifestations include acute anterior uveitis (requires urgent treatment), aortitis, and apical pulmonary fibrosis
- HLA-B27 is risk factor, not diagnostic test; 6-8% of general population is positive, most never develop SpA

## References

1. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599-1613.

2. Rudwaleit M, van der Heijde D, Landewé R, et al. The Development of Assessment of SpondyloArthritis International Society Classification Criteria for Axial Spondyloarthritis (Part II): Validation and Final Selection. Ann Rheum Dis. 2009;68(6):777-783.

3. Taylor W, Gladman D, Helliwell P, et al. Classification Criteria for Psoriatic Arthritis: Development of New Criteria from a Large International Study. Arthritis Rheum. 2006;54(8):2665-2673.

4. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2019 Update. Ann Rheum Dis. 2020;79(6):700-712.

5. Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015;373(26):2534-2548.

6. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an Interleukin-17A Specific Monoclonal Antibody, for the Treatment of Biologic-Naive Patients with Active Psoriatic Arthritis: Results from the 24-Week Randomised, Double-Blind, Placebo-Controlled and Active (Adalimumab)-Controlled Period of the Phase III Trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79-87.

7. Carter JD, Hudson AP. Reactive Arthritis: Clinical Aspects and Medical Management. Rheum Dis Clin North Am. 2009;35(1):21-44.

8. Sieper J, Poddubnyy D. Axial Spondyloarthritis. Lancet. 2017;390(10089):73-84.

9. McGonagle D, Gibbon W, Emery P. Classification of Inflammatory Arthritis by Enthesitis. Lancet. 1998;352(9134):1137-1140.

10. van der Heijde D, Ramiro S, Landewé R, et al. 2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-991.
